SnowWorld N.V. — Earnings Release 2005

Jan 5, 2006

==> picture [139 x 92] intentionally omitted <==

P R E S S R E L E A S E

Lelystad, 5 January 2006

Fornix BioSciences upgrades 2005 turnover and profit forecast

• Projected growth in 2005 net profit of at least 45% (was at least 35%)

• Projected turnover growth of 14% (was 10%)

• Allergy Division’s performance in November and December 2005 exceeded expectations

Biopharmaceutical company Fornix BioSciences (Euronext: AFORBI) has upgraded its profit and turnover forecast for 2005. According to the latest figures, net profit for 2005 will be at least € 9.6 million, an increase of at least 45% on 2004 ( € 6.6 million). Consolidated turnover is expected to rise to € 87.7 million, up more than 14% on 2004 ( € 76.6 million).

In a previous update on 3 November, Fornix announced that it was expecting net profit growth of at least 35% and turnover growth of 10% in 2005.

The upward revision announced today is due entirely to the performance of the Allergy Division in November and December, which turned out far better than predicted.

More detailed provisional information on Fornix’s operations and results in 2005 will be published before start of trading on 24 January 2006.

Note for editors

For more information: C.L. Bergman, CEO Fornix BioSciences N.V. Tel. +31 320 267 799 www.fornix.nl

1

Profile of Fornix BioSciences N.V.

Fornix BioSciences N.V., which has its headquarters in Lelystad (Netherlands) and a total workforce of around 180, engages in the production, marketing and sale of therapeutic antiallergy products and medical aids and the purchasing, marketing and distribution of patented pharmaceuticals. The activities are carried on by three divisions, which in turn are made up of operating companies. The Allergy Division, consisting of ARTU Biologicals, specialises in the production and sale of anti-allergy products. The Trading Division, consisting of Fisher Farma, trades in patented pharmaceuticals. The newly formed Medical Aids Division consists of Laprolan, which specialises in the marketing, sale and distribution of medical and nursing consumables, and Artu Medical, which specialises in the marketing and sale of medical aids such as silicon dressings and hip protectors.

Fornix BioSciences N.V. shares are listed on the Official Market of the Euronext Amsterdam stock exchange (code AFORBI).

E N D O F P R E S S R E L E A S E

2